Stock IXHL INCANNEX HEALTHCARE INC.
Add to a list
To use this feature you must be a member
Log inSign up

Incannex Healthcare Inc. Stock

Equities

IXHL

US45333F1093

Pharmaceuticals

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-30 pm EDT 		5-day change 1st Jan Change
2.89 USD +14.68% Intraday chart for Incannex Healthcare Inc. +26.75% -37.72%
Mar. 05 Incannex Healthcare Inc. Announces CFO Changes CI
Mar. 05 Incannex Healthcare Inc. Announces Executive Changes CI

Financials

Sales 2022 782K 507K Sales 2023 1.01M 657K Capitalization 4.37B 2.83B
Net income 2022 -14M -9.07M Net income 2023 -20M -12.96M EV / Sales 2022 9,113 x
Net cash position 2022 37.5M 24.3M Net cash position 2023 32.58M 21.11M EV / Sales 2023 4,281 x
P/E ratio 2022
-447 x
P/E ratio 2023
-212 x
Employees 3
Yield 2022 *
-
Yield 2023
-
Free-Float 78.46%
More Fundamentals * Assessed data

Chart Incannex Healthcare Inc.

Dynamic Chart

Latest news about Incannex Healthcare Inc.

Incannex Healthcare Inc. Announces CFO Changes CI
Incannex Healthcare Inc. Announces Executive Changes CI
Incannex Announces Positive Topline Results from Phase 2 Psi-GAD1 Clinical Trial of Psilocybin in Generalised Anxiety Disorder CI
Incannex Healthcare Completes Pre-Investigational New Drug Meeting on CannQuit-N With US FDA MT
Incannex Healthcare Inc. Completes Successful Pre-IND Meeting with the FDA for CannQuit-N CI
Incannex Healthcare Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023 CI
Incannex Commences Dosing in Phase 2 Clinical Trial Assessing IHL-675A in Patients with Rheumatoid Arthritis CI
Incannex Completes Dosing and Therapy in Phase 2 ?Psigad? Clinical Trial Assessing Psilocybin-Assisted Psychotherapy for Generalized Anxiety Disorder CI
Incannex Healthcare Gets Institutional Review Board Approval For IHL-42X Drug Trial MT
Incannex Healthcare Inc. Receives IRB Approval for the Reposa Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea CI
Incannex Healthcare Ltd. Receives Ethics Board Endorsement for Psychedelic Assisted Therapy At Its First Clinic Based in Melbourne, Australia CI
Incannex Healthcare Inc Update on Ihl-42X Drug Candidate in Phase 2/3 Clinical Trial in Obstructive Sleep Apnea CI
Incannex Healthcare Inc. Reports Earnings Results for the Full Year Ended June 30, 2023 CI
Incannex Healthcare Inc. Reports Earnings Results for the Half Year Ended December 31, 2022 CI
More news

Press releases Incannex Healthcare Inc.

Incannex Healthcare Inc. Quarterly Update, Q1 2024 AQ
Incannex Announces Positive Topline Results from Phase 2 Psi-GAD1 Clinical Trial of Psilocybin in Generalised Anxiety Disorder AQ
Incannex Completes Successful Pre-IND Meeting with the FDA for CannQuit-N; a Novel Solution for Tobacco Smoking Cessation AQ
Clarion Clinics Open for Psychedelic-Assisted Treatments AQ
Incannex Commences Dosing in Phase 2 Clinical Trial Assessing IHL-675A in Patients with Rheumatoid Arthritis AQ
More press releases

Quotes and Performance

1 day+14.68%
1 week+26.75%
1 month-19.50%
3 months-15.99%
6 months-31.19%
Current year-37.72%
More quotes

Highs and lows

1 week
2.20
Extreme 2.2
2.94
1 month
2.13
Extreme 2.13
3.50
Current year
2.13
Extreme 2.13
8.47
1 year
1.96
Extreme 1.96
12.68
3 years
1.96
Extreme 1.96
360.00
5 years
1.96
Extreme 1.96
360.00
10 years
1.96
Extreme 1.96
360.00
More quotes

Quotes

Date Price Change Volume
24-04-30 2.89 +14.68% 27,974
24-04-29 2.52 +13.51% 17,658
24-04-26 2.22 -3.48% 8,720
24-04-25 2.3 +1.77% 3,855
24-04-24 2.26 -0.88% 31,579

Delayed Quote Nasdaq, April 30, 2024 at 04:00 pm EDT

More quotes

Company Profile

Incannex Healthcare Inc. is a clinical-stage pharmaceutical development company. The Company is developing medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for the treatment of obstructive sleep apnea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, and pain, among other indications. The Company’s diversified portfolio includes 28 distinct research and development (R&D) programs, and six clinical trials underway. Its clinical projects include IHL-42X Obstructive Sleep Apnea, IHL-675A Inflammatory Lung Disease, IHL-675A Rheumatoid Arthritis, IHL-675A Inflammatory Bowel Disease, IHL-216A Concussion and TBI, PSI-GAD Psilocybin for anxiety, MedChew GB Post-herpatic Neuralgia and MedChew -1401 Pain and Spasticity in Multiple Sclerosis.
Sector
Pharmaceuticals
Calendar
2024-08-27 - Q4 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Alternative Medicine

1st Jan change Capi.
INCANNEX HEALTHCARE INC. Stock Incannex Healthcare Inc.
-37.72% 45.87M
DONG-E-E-JIAO CO.,LTD. Stock Dong-E-E-Jiao Co.,Ltd.
+39.33% 6.11B
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD. Stock Shijiazhuang Yiling Pharmaceutical Co., Ltd.
-18.38% 4.35B
TASLY PHARMACEUTICAL GROUP CO., LTD Stock Tasly Pharmaceutical Group Co., Ltd
-9.17% 3.18B
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED Stock Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited
+3.98% 3.16B
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD. Stock Shandong Buchang Pharmaceuticals Co., Ltd.
-3.41% 2.51B
HENAN LINGRUI PHARMACEUTICAL CO., LTD. Stock Henan Lingrui Pharmaceutical Co., Ltd.
+48.74% 1.98B
GUANGYUYUAN CHINESE HERBAL MEDICINE CO., LTD. Stock GuangYuYuan Chinese Herbal Medicine Co., Ltd.
-4.82% 1.74B
TIBET CHEEZHENG TIBETAN MEDICINE CO., LTD. Stock Tibet Cheezheng Tibetan Medicine Co., Ltd.
-1.24% 1.63B
TIANJIN CHASE SUN PHARMACEUTICAL CO.,LTD Stock Tianjin Chase Sun Pharmaceutical Co.,Ltd
-8.96% 1.6B
Alternative Medicine
  1. Stock Market
  2. Equities
  3. IXHL Stock